^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    seclidemstat (SP2577)

    i
    Company:
    Salarius
    Drug class:
    LSD1 inhibitor
    Related drugs:
    Apply
    Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    07/07/2021
    Primary completion :
    09/11/2025
    Completion :
    09/11/2025
    TP53 • NRAS • RUNX1 • ASXL1 • SETBP1
    |
    TP53 mutation • NRAS mutation • ASXL1 mutation
    |
    azacitidine • seclidemstat (SP2577)
    Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas (SALA-002-EW16) (NCT03600649)
    Phase 1
    Salarius Pharmaceuticals, LLC
    Active, not recruiting
    Last update posted :
    11/21/2023
    Initiation :
    06/04/2018
    Primary completion :
    09/01/2025
    Completion :
    12/01/2025
    EWSR1
    |
    cyclophosphamide • topotecan • seclidemstat (SP2577)
    Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers (NCT04611139)
    Phase 1
    HonorHealth Research Institute
    Withdrawn
    Last update posted :
    03/01/2022
    Initiation :
    12/31/2021
    Primary completion :
    12/31/2023
    Completion :
    06/30/2024
    ARID1A
    |
    ARID1A mutation
    |
    Keytruda (pembrolizumab) • seclidemstat (SP2577)